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genomes encode 121 and 79 V2R genes, 
respectively) (Young and Trask, 2007). 
Conversely, functional V2Rs are absent 
in other mammalian species, such as 
dogs or apes, in which only a single Mup 
gene has been found. An apparent cor-
relation thus exists between the expan-
sion of the V2R gene repertoires and 
the Mup gene repertoires in mice and 
rats. The strength of this correlation will 
soon be put to the test by comparative 
genomics of different rodent species. In 
parallel, the functional relevance could 
be evaluated by the potentially altered 
response to kairomones of mice lack-
ing β2-microglobulin, a critical player in 
targeting V2Rs to the plasma membrane 
(Loconto et al., 2003). Thus, the identi-
fication of Mups as triggers of distinct 
and very robust hard-wired behavioral 
responses in mice is likely to lead to new 
insights into the coding strategies under-
lying rodent innate behaviors.
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To defend cells against viruses, the MAVS (mitochondrial antiviral signaling) adaptor protein initi-
ates an antiviral signaling cascade from mitochondrial membranes. In this issue, Dixit et al. (2010) 
show that MAVS also localizes to the membranes of peroxisomes, where it rapidly induces expres-
sion of a subset of antiviral genes that curb viral replication until mitochondrial MAVS can induce 
a sustained antiviral response.To survive a viral infection, the immune 
system triggers an arsenal of protective 
defense measures. One of the most potent 
of these is the induction of type I interfer-
ons. These cytokines orchestrate both 
rapid and long-term responses that inhibit 
viral replication and assembly. Immune 
sensors inside cells detect viral genomes 
or the replicative activities of viruses to ini-
tiate this antiviral state (Takeuchi and Akira, 
2009). In the case of RNA viruses, the RNA 
helicases retinoic acid-inducible gene 
I (RIG-I) and melanoma differentiation-
associated gene 5 (MDA-5) discriminate 
between different classes of RNA viruses 
in the cytosol (Figure 1). RIG-I senses the 
5′ triphosphate moiety of viral genomes or 
short blunt-ended double-stranded RNA 
molecules, while MDA-5 recognizes long 570 Cell 141, May 14, 2010 ©2010 Elsevier Idouble-stranded RNA molecules (a typi-
cal intermediate during the replication of 
certain viruses). Upon binding to these 
viral components, both RIG-I and MDA-5 
then interact with MAVS (also called IPS-1, 
Cardif, or VISA), which triggers an antiviral 
signaling cascade. This leads to the acti-
vation of NF-κB and interferon regulatory 
factor 3 (IRF3), which subsequently turn on 
the expression of genes encoding inflam-
matory cytokines and type I interferons 
(Figure 1).
MAVS contains a C-terminal trans-
membrane domain, which targets the 
protein to the outer membrane of mito-
chondria. This localization of MAVS is 
essential for signaling because cleavage, 
deletion, or mutation of the mitochondrial-
targeting sequence of MAVS disrupts the nc.antiviral response (Li et al., 2005; Seth 
et al., 2005; Meylan et al., 2005). In this 
issue of Cell, Dixit et al. (2010) now show 
that MAVS is also found on other mem-
brane-bound organelles in the cytosol 
called peroxisomes. Peroxisomal MAVS 
establishes an immediate albeit transient 
antiviral response, which halts or delays 
viral replication until the more robust and 
sustained antiviral response driven by the 
mitochondrial MAVS pathway comes into 
play.
Peroxisomes, best known for their role 
in the oxidation of lipids, contain a large 
number of oxidative enzymes within their 
lumen. Peroxisomes originate from the 
endoplasmic reticulum (ER), but they 
freely exchange proteins with mitochon-
dria (Camões et al., 2009). MAVS is not 
associated with the ER, the plasma 
membrane, or the endocytic system 
that imports proteins from the plasma 
membrane to the cell interior (Seth et al., 
2005). However, the C-terminal tail that 
anchors MAVS to mitochondrial mem-
branes is similar to targeting motifs in 
mitochondrial fission 1 (Fis-1) protein and 
mitochondrial fission factor (Mff) protein, 
which both localize not only to mito-
chondrial membranes but also to those 
of peroxisomes (Gandre-Babbe and van 
der Bliek, 2008; Koch et al., 2005).
This sequence similarity and the con-
siderable membrane crosstalk between 
peroxisomes and mitochondria (Camões 
et al., 2009) prompted Dixit et al. (2010) 
to check whether MAVS also localizes 
to peroxisomes. Indeed, they found that 
MAVS constitutively associates with both 
mitochondria and peroxisomes in mouse 
and human cells. They initially hypoth-
esized that the role of peroxisomes was 
simply to route MAVS correctly to mito-
chondria. However, the delivery of MAVS 
to the mitochondria was normal in cells 
that lacked peroxisomes. Thus, to deter-
mine the purpose of MAVS in peroxi-
somes, the authors generated cell lines 
in which the C-terminal localization motif 
of MAVS was either deleted or replaced 
with another motif known to target pro-
teins to a single compartment of the cell. 
This created three different versions of 
MAVS that each localized exclusively to 
the cytosol, mitochondrial membranes, 
or peroxisomal membranes. Except for 
the cytosolic form, each MAVS vari-
ant induced the production of a well-
characterized antiviral protein, viperin, 
in response to infection with reovirus, 
which signals via RIG-I and MDA-5 
(Loo et al., 2008). Interestingly, although 
MAVS on peroxisomes or wild-type 
MAVS induced production of viperin 
within 4 hr of reovirus infection, expres-
sion of MAVS exclusively on mitochon-
dria significantly delayed induction of 
this interferon-stimulated gene product. 
Further analysis of other interferon-stim-
ulated genes indicated that the signal-
ing pathways triggered by peroxisomal 
MAVS contribute to a more rapid (albeit 
transient) induction of these antiviral fac-
tors after reovirus infection. Mitochon-
drial MAVS also induced the expres-
sion of interferon-stimulated genes, but 
the kinetics was significantly slower. figure 1. Organelle-specific MAVs signaling
The RNA helicases retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 
(MDA-5) are part of the immune system’s antiviral defense system. These proteins detect viral RNA and 
then interact with MAVS, an adaptor molecule on mitochondrial membranes. Detection of viral nucleic 
acids by these helicases and signaling via mitochondrial MAVS induces the expression of type I interfer-
ons (IFNs) and eventually leads to virus control. Dixit et al. (2010) now show that MAVS is also present 
on metabolic organelles called peroxisomes. Peroxisomal MAVS is essential for the rapid expression of 
antiviral genes called interferon-stimulated genes (ISGs). This gene expression, which is independent of 
type I IFN production, results in an early but transient antiviral response. However, type I IFN induction 
by the mitochondrial MAVS pathway is necessary for the eventual clearance of the virus. The different 
outcomes observed for the two MAVS pathways may relate to the fact that peroxisomal MAVS activates 
interferon regulatory factor 1 (IRF1) in addition to IRF3. It is possible that an IRF1-IRF3 heterodimer in-
duces expression of ISGs but not type I IFN genes. These studies reveal that MAVS signaling from both 
peroxisomes and mitochondria is necessary for maximal containment of virus replication.Cell 141, May 14, 2010 ©2010 Elsevier Inc. 571
The authors obtained similar results 
when they infected cells with influenza 
virus, which activates MAVS exclusively 
through interactions with RIG-I.
In contrast to cells with mitochondrial 
MAVS, those with peroxisomal MAVS did 
not produce type I interferons, indicat-
ing that these potent antiviral cytokines 
are not a prerequisite for the induction of 
viperin by MAVS signaling from peroxi-
somes. Strikingly, Dixit and colleagues 
found that cells with peroxisomal MAVS 
were as efficient at controlling the repli-
cation of vesicular stomatitis virus (VSV) 
as cells with wild-type MAVS. VSV fails 
to induce type I interferons, but it still 
induces interferon-stimulated genes, 
like viperin (Ferran and Lucas-Lenard, 
1997). Thus, these important findings 
indicate that peroxisomal MAVS plays a 
bona fide role in controlling viral infec-
tion independently of type I interferons 
and most probably does so through the 
early induction of interferon-stimulated 
genes, such as viperin and ISG15 (a 
ubiquitin-like protein that inhibits viral 
production) (Figure 1).
This study highlights a number of 
important new themes. First, it reveals 
that peroxisomes are not simply meta-
bolic organelles but rather serve as sig-
naling platforms to orchestrate an imme-
diate immune response against virus 
infection. This early antiviral state curbs 
the infection until enough interferon is 
produced to induce the expression of a 572 Cell 141, May 14, 2010 ©2010 Elsevier Incomplete panel of interferon-stimulated 
genes and to halt viral replication per-
manently. Second, the study demon-
strates that early expression of a subset 
of antiviral genes can control viral infec-
tion independently of type I interferon 
production. An extremely interesting 
conundrum raised by these studies is the 
apparent failure of peroxisomal MAVS 
signaling to stimulate the expression of 
type I interferon genes even though this 
MAVS still activates IRF3 (Figure 1). The 
peroxisomal pathway also uses IRF1; 
thus, perhaps a heterodimeric complex 
of IRF1 and IRF3 favors transcription of 
interferon-stimulated genes but not that 
of type I interferon genes.
This exciting study also indicates how 
distinct temporal and compartmental-
ized antiviral responses from peroxi-
somal and mitochondrial MAVS have 
clear advantages for the host. Viruses are 
skilled pathogens, which can evade or 
subvert innate signaling pathways. Pre-
vious work has revealed that the NS3-4A 
serine protease from Hepatitis C virus 
cleaves MAVS from the mitochondrial 
membrane, thereby inactivating antiviral 
defenses. It will be important to deter-
mine whether NS3-4A also affects the 
peroxisomal MAVS pathway or whether 
this pathway is still functional. Undoubt-
edly, future studies will unveil additional 
immune evasion strategies employed by 
other viruses to subvert the early wave 
of interferon-stimulated gene expres-c.sion induced by peroxisomal MAVS. In 
this context, it will be of great interest to 
further elaborate the molecular basis for 
peroxisomal MAVS signaling and delin-
eate its role in the regulation of all MAVS-
dependent antiviral responses.
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